Sharechat Logo

MARKET CLOSE: NZ shares fall, MetroGlass sinks to record low, F&P Healthcare, Fletcher, A2 slide

Wednesday 7th March 2018

Text too small?

New Zealand shares fell as Metro Performance Glass sank to a record low on speculation it may drop out of the S&P/NZX 50 Index. Fisher & Paykel Healthcare, Fletcher Building and a2 Milk were among decliners while Kathmandu and Z Energy rose.

The NZX 50 fell 43.32 points, or 0.5 percent, to 8,284.34. Within the index, 24 stocks declined, 17 rose and nine were unchanged. Turnover was $184 million. 

MetroGlass dropped 2.5 percent to 79 cents, a record low close. They sold in the 2014 IPO for $1.70 a share, allowing private equity owners Crescent Capital and Anchorage Capital to reap about $230 million selling down their holdings. Like Fletcher and Steel & Tube, MetroGlass has grappled with capacity constraints in the construction industry, which has squeezed margins. In October it announced a strategic review after a series of guidance downgrades and chief executive Nigel Rigby stepped down in December. March quarter reweightings for the NZX 50 may be announced as soon as this week.

Investors "are speculating that MetroGlass will be taken out of the 50," said Rickey Ward, NZ equity manager at JBWere. "The market cap has come down and people are repositioning" ahead of the March quarter rebalance.

Fletcher dropped 1.8 percent to $6.49 although Ward said chief executive Ross Taylor "has been talking a very credible story" about trying to ringfence losses at the company's B+I unit while completing a strategic review of the whole group. Steel & Tube declined 0.5 percent to $2.08.

Ward said New Zealand shares also fell today in an environment "where people are a little bit more cautious." Global events including the uncertainty over Italy's elections were "weighing on risk appetite globally." The S&P/ASX 200 Index was down 1.1 percent today.

Investors in New Zealand shares were also digesting the latest earnings season, where a number of companies had retained their guidance but that had led to some analyst downgrades given "valuations have been confirmed to be a little bit stretched at the moment," Ward said.

A2 fell 1.5 percent to $12.56, having soared 58 percent this year. Ward said it has continued to drift after its "extreme run" and also on news that management had been selling shares. Synlait Milk decreased 0.1 percent to $7.49 and honey products exporter Comvita fell 1.3 percent to $7.40.

Westpac Banking Corp declined 2 percent to $31.95 and Australia & New Zealand Banking Group fell 1.9 percent to $30.13, reflecting the lenders' weaker stock across the Tasman.

F&P Healthcare fell 3.3 percent to $13.25 and Ryman Healthcare fell about 1 percent to $10.40. Kathmandu rose 2.7 percent to $2.28 and Z Energy rose 1.7 percent to $7.

Marsden Maritime Holdings was unchanged at $5.60 after chief executive Graham Wallace said he will leave the company at the end of this month.

(BusinessDesk)

  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

MARKET CLOSE: NZ shares gain as upcoming Fed meeting bolsters yield stocks; Sky TV gains
ESW reaches 90% of SLI Systems, moves to compulsory acquisition
NZ higher against USD as markets await the US Federal Reserve
Hawke's Bay council advances Napier Port IPO plan
Government outlines planned hikes in minimum wage
Chorus could lift its dividend post-UFB rollout but risks remain
T&G Global profit dented by cheaper tomatoes, small grape harvest
NZ posts widest current account deficit since 2009, in line with expectations
Heartland says new bank capital rules won't hurt as much as the market thinks
ISS supports Vital Healthcare's rebel investors

IRG See IRG research reports